Amgen beats revenue and profit expectations in Q1, plans to focus on product launches and growth

From StockStory Inc.: 2025-05-15 16:42:00

Amgen (NASDAQ:AMGN) reported Q1 CY2025 revenue of $8.15 billion, beating analyst estimates by 1.5%. The company’s non-GAAP profit of $4.90 per share exceeded expectations by 15%. Full-year revenue guidance is $35 billion. Management highlighted growth in various product categories and the launch of new therapies. Amgen’s stock trades at a forward P/E ratio of 13x.

Looking ahead, Amgen plans to focus on late-stage clinical trials and new product launches. The company aims to expand its biosimilars portfolio and navigate policy changes. Analysts are monitoring key data releases and commercial adoption of new therapies in upcoming quarters.



Read more at StockStory Inc.: Product Pipeline and Margin Expansion Drive Outperformance